**8. References**

Abramson, F.P. Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein. *Clin Pharmaco Ther.* 1982. 32(5): 652-658.

Variability of Plasma Methadone Concentration in Opiate Dependent

implications. *J Psychoactive Drug.* 2006. 38(4): 513-519.

*The International Journal on Drug Policy.* 2009. 20(4): 304-308.

treatment. *Drug and Alcohol Dependence.* 1992. 30(3): 241-246.

*journal of clinical pharmacology.* 1981. 20(6): 473-478-478.

*Clin Pharmaco Ther.* 1981. 29(2): 211-217.

outpatient pain centers. *Pharmacogenetics and Genomics.* 2009. 19(6):

*Therapeutics.* 2005. 28(5): 461-466.

Donica Publishing. 2002. 75-76.

2008. 12(2): 109-124.

19595-19600.

Receiving Methadone: A Personalised Approach Towards Optimizing Dose 141

KuKanich, B. & Borum, S.L. The disposition and behavioral effects of methadone in Greyhounds. *Veterinary Anaesthesia and Analgesia.* 2008. 35(3): 242-248. Kukanich, B., Lascelles, B.D.X., Aman, A.M., Mealey, K.L. & Papich, M.G. The effects of

Latowsky, M. Methadone death, dosage and torsade de pointes: risk-benefit policy

Liu, E., Liang, T., Shen, L., Zhong, H., Wang, B., Wu, Z. & Detels, R. Correlates of

Li, X. & Wei, W. Chinese materia medica: combinations and appication Hertfordshire:

Li, Y., Kantelip, J.P., Gerritsen-van, S.P. & Davani, S. Interindividual variability of

Loimer, N. & Schmid, R. The use of plasma levels to optimize methadone maintenance

Lötsch, J., von Hentig, N., Freynhagen, R., Griessinger, N., Zimmermann, M., Doehring, A.,

Mattick, R.P., Breen, C. and Kimbler, J. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Syst Rev.* 2003. Meresaar, U., Nilsson, M.I., Holmstrand, J. & Änggård, E. Single dose pharmacokinetics and

Mestriner, F.L.A.C., Spiller, F., Laure, H.J., Souto, F.O., Tavares-Murta, B.M., Rosa, J.C.,

Romach, M.K., Piafsky, K.M., Abel, J.G., Khouw, V. & Sellers, E.M. Methadone binding to

Rostami-Hodjegan, A., Wolff, K., Hay, A.W.M., Raistrick, D., Calvert, R. & Tucker, G.T.

Sawe, J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. *Clin Pharmacokinet.* 1986. 11(2): 87-106. Schmidt, N., Sittl, R., Brune, K. & Geisslinger, G. Rapid Determination of Methadone in

Philadelphia: Lippincott Williams & Wilkins. 1995. 137–155.

inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. *Journal of Veterinary Pharmacology and* 

methadone client retention: a prospective cohort study in Guizhou province, China.

methadone response: impact of genetic polymorphism [Abstract]. *Mol Diagn Ther.* 

Rohrbacher, M., Sittl, R. & Geisslinger, G. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in

bioavailability of methadone in man studied with a stable isotope method. *European* 

Basile-Filho, A., Ferreira, S.H., Greene, L.J. & Cunha, F.Q. Acute-phase protein α-1 acid glycoprotein mediates neutrophil migration failure in sepsis by a nitric oxidedependent mechanism. *Proceedings of the National Academy of Sciences.* 2007. 104(49):

orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma.

Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. *British Journal of Clinical Pharmacology.* 1999. 48(1): 43-52. Rowland, M. & Tozer, T.N. Physiologic concepts and kinetics: distribution. In Rowland, M.

and Tozer, T. N. (Eds.), *Clinical Pharmacokinetics. Concepts and Applications*. 3rd ed.

Plasma, Cerebrospinal Fluid, and Urine by Gas Chromatography and Its


Brady, T.M., Salvucci, S., Sverdlov, L.S., Male, A., Kyeyune, H., Sikali, E., DeSale, S. and Yu,

de Vos, J.W., Ufkes, J.G.R., van Brussel, G.H.A. & van den Brink, W. Craving despite

Dyer, K.R., Foster, D.J.R., White, J.M., Somogyi, A.A., Menelaou, A. & Bochner, F. Steady-

Eap, C.B., Cuendet, C. & Baumann, P. Binding of d-methadone, l-methadone, and dl-

Ekblom, M., Hammarlund-Udenaes, M. & Paalzow, L. Modeling of tolerance development

http://www.fhi.org/training/en/HIVAIDS/IDUModules/pdf/Module\_04\_Treat

Fanoe, S., Hvidt, C., Ege, P. and Jensen, G.B. Syncope and QT prolongation among patients

Farré, M., Mas, A., Torrens, M., Moreno, V. and CamI, J. Retention rate and illicit opioid use

Fournier, T., Medjoubi-N, N. & Porquet, D. Alpha-1-acid glycoprotein. *Biochimica et* 

Garrido, M.J., Aguirre, C., Trocóniz, I.F., Marot, M., Valle, M., Zamacona, M.K. and Calvo, R.

Gómez, E., Martinez-Jordá, R., Suárez, E., Garrido, M.J. & Calvo, R. Altered methadone

Inturrisi, C.E., Portenoy, R.K., Max, M.B., Colburn, W.A. & Foley, K.M. Pharmacokinetic-

*Journal of Addictive Diseases.* 2005. 24(3): 23-47.

dependence. . *Clin. Pharmacokinet.* 2002. 41(1153-1193.

positive injecting drug users Disember 27,2009, from

ment\_Care\_for\_HIV\_positive\_IDUs.pdf

2007. 93(9): 1051-1055.

2001. 299(1): 366-371.

pain. *Clin Pharmaco Ther.* 1990. 47(5): 565-577.

157-171.

40.

*Dependence.* 2002. 65(3): 283-290.

1-acid glycoprotein. *Clin Pharmaco Ther.* 1990. 47(3): 338-346.

184.

P. Methadone dosage and retention: an examination of the 60 mg/day threshold.

extremely high methadone dosage. *Drug and Alcohol Dependence.* 1996. 40(3): 181-

state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships[ast]. *Clin Pharmacol Ther.* 1999. 65(6): 685-694. Eap, C.B., Buclin, T. & Baumann, P. Interindividual variability of the clinical

pharmacokinetics of methadone: implications for the treatment of opioid

methadone to proteins in plasma of healthy volunteers: role of the variants of alpha

and rebound effect during different intravenous administrations of morphine to rats. *Journal of Pharmacology and Experimental Therapeutics.* 1993. 266(1): 244-252. Family Health International. Managing opioid dependence: treatment and care for HIV-

treated with methadone for heroin dependence in the city of Copenhagen. *Heart.* 

during methadone maintenance interventions: a meta-analysis. *Drug and Alcohol* 

*Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology.* 2000. 1482(1-2):

Alpha 1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome. *Int J Clin pharmaco Ther.* 2000. 38(1): 35-

analgesia due to changes in plasma protein binding: Role of the route of administration. *General Pharmacology: The Vascular System.* 1995. 26(6): 1273- 1276.Xiao, Y., Smith, R.D., Caruso, F.S. & Kellar, K.J. Blockade of Rat α3β4 Nicotinic Receptor function by Methadone, its metabolites, and structural analogs. *JPET.* 

pharmacodynamic relationships of methadone infusions in patients with cancer


**7** 

*Egypt* 

**Drug Synergy –** 

Hans-Georg Breitinger *The German University in Cairo,* 

**Mechanisms and Methods of Analysis** 

The term synergy is derived from the Greek *syn-ergos*, "working together". Synergies have been described in many settings and situations of life, including mechanics, technical systems, human social life, and many more. In all cases, synergy describes the fact that a system, i.e. the combination and interaction of two or more agents or forces is such that the

This definition implies that there are three possible ways of such an "interaction of agents or forces": these forces could simply add up, not affecting each other (no interaction), their combination could produce a greater than expected result (synergy), or the combination could lead to a result that is less than the sum of the individual effects. This "negative"

Interactions of biologically active agents are an important aspect of pharmacology and biomedicine. In this context, interaction describes the biological activity that results from the presence of several drugs at the same time. Such situations occur in numerous clinical



In all these cases, multiple drugs are administered, and will show some form of interaction, synergistic, antagonistic, or none. Methods to determine and quantify drug interactions are thus an essential tool in pharmacology. Historically, extracts from plants, animals, or even soils were the first classified pharmaceuticals. These were complex mixtures rather than single agents, and some ingredients may have interacted with others. Over the years of development of pharmacy, isolation, synthesis and marketing of single drugs became the accepted standard. Whether a complex mixture or a combination of drugs is used, the biological interaction of all active substances should be known. Synergy may be observed in simple systems – two drugs that only act on one target protein can show synergism. In such a case we can study the interaction of the drugs mechanistically and determine why and

combined effect is greater than the sum of their individual effects.

**1. Introduction** 

situations:

summation is called antagonism.

an effect on its own

and reduced development of resistance.

Application to Routine Drug Monitoring. *Pharmaceutical Research.* 1993. 10(3): 441- 444-444.

